FENTANYL CITRATE INJECTION USP SOLUTION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
24-05-2022
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
FENTANYL (FENTANYL CITRATE)
Tillgänglig från:
HIKMA CANADA LIMITED
ATC-kod:
N02AB03
INN (International namn):
FENTANYL
Dos:
50MCG
Läkemedelsform:
SOLUTION
Sammansättning:
FENTANYL (FENTANYL CITRATE) 50MCG
Administreringssätt:
INTRAMUSCULAR
Enheter i paketet:
2ML/10ML
Receptbelagda typ:
Narcotic (CDSA I)
Terapiområde:
OPIATE AGONISTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0123302011; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2021-09-02
Produktens egenskaper
Fentanyl Citrate Injection USP
Page 1 of 44
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
FENTANYL CITRATE INJECTION USP
(fentanyl 50 mcg / mL as fentanyl citrate)
Narcotic Analgesic
Adjunct to Anesthesia
Hikma Canada Limited
5995 Avebury Road, Suite 804
Mississauga, Ontario
L5R 3P9
Date of Preparation: May 24, 2022
Control No. 263327
Fentanyl Citrate Injection USP
Page 2 of 44
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...........................................................3
SUMMARY PRODUCT
INFORMATION....................................................................3
INDICATIONS AND CLINICAL
USE..........................................................................3
CONTRAINDICATIONS.............................................................................................4
WARNINGS AND
PRECAUTIONS............................................................................4
ADVERSE
REACTIONS...........................................................................................12
DRUG
INTERACTIONS............................................................................................14
DOSAGE AND
ADMINISTRATION..........................................................................15
OVERDOSAGE........................................................................................................21
ACTION AND CLINICAL
PHARMACOLOGY..........................................................21
STORAGE AND
STABILITY....................................................................................24
SPECIAL HANDLING
INSTRUCTIONS..................................................................24
DOSAGE FORMS, COMPOSITION, AND
PACKAGING........................................25
PART II: SCIENTIFIC
INFORMATION...............................................................................26
PHARMACEUTICAL
INFORMATION.....................................................................26
DETAILED
PHARMACOLOGY.................................................................
Läs hela dokumentet
